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ABSTRACT. Objective: There are many health risks involved with the use of weight loss
products by normal weight women. The mass media may compound this problem through
the promotion of weight loss products and a thin body size. This study tested women's perceptions of different weight loss product ads to detern1ine if body dysphoria (i.e., an over
concern with body size and shape in normal weight people) was associated with risk beliefs,
past behaviors, and intention toward using weight loss products. Method: Normal weight
women (age range = 18-41 yr), who were classified as either high (n=45) or low (n=43) on a
measure of body dysphoria, rated different weight loss products according to their perception of health risks, past behavior, and their intention to consume the products. These products were a dietary fat substitute (olestraJ a prescription obesity medication (sibutramine),
and an over-the-counter appetite suppressant (phenylpropanolamine). Results: High body
dysphoric women reported higher intentions to use the products as well as increased prior
use of two of the three weight loss products. High body dysphoric women did not believe
that these weight loss products were harmless. They recognized potential health risks associated with using such products, but nonetheless, expressed intention to use these weight loss
products at a higher frequency. Also, several variables related to body image were found to
effectively discriminate normal weight women at risk for abusing weight loss products.
Discussion: This study found that women who do not need to lose weight but have significant body image concerns were willing to use potentially harmful weight loss products
despite the knowledge that such products might pose significant health risks. Techniques utilized by advertising regulatory agencies such as warning labels did not have a strong deterrent effect for stated intentions to use the products. Implications of these findings for public
health policy issues were discussed.
(Eating Weight Disord. 8: 114-123,2003). ©2003, Editrice Kurtis
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Problems related to being overweight are
estimated to account for 70 billion dollars
annually in the United Statesin health-related costs (1). In addition, 33 billion dollars
are spent per year on diet pills, exercise
programs, and appetite suppressants, making dieting the norm rather than the exception (2). A recent report of a mUlti-agency
conference on weight loss products and
programs sponsored by the Federal Trade
Commission (FTC), American Society for
Clinical Nutrition, National Institute of
Diabetes, and the Center for Disease
Control and Prevention estimates that 40%
of women in the U.S. are currently trying to

lose weight (1). The primary reason for trying to lose weight is "a concern for physical
appearance," and many of those attempting
to lose weight are not overweight (based on
height/weight ratios), i.e., normal weight
women (1).
Ads promoting the use of weight loss
products typically aim to promote a healthier lifestyle. However, these same ads may
be interpreted in ways that are unhealthy
by a minority of people who are "at risk"
for psychological/physical problems (e.g.,
women with eating disorders). Several
studies suggest that a motivating factor for
unhealthy weight reduction behaviors may
be media pressure in the form of weight
loss ads. For example, Burton et a1. (3) and
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Whisenhunt et al. (4) found a significant relationship between images in weight loss ads and
unhealthy dieting behaviors. Rabak-Wagner et
al. (5) reported that a primary factor affecting
unhealthy dieting in college-aged women is the
information in ads for weight loss products.
Grigg et al. (6) found that over half of the adolescent girls they sampled had used at least one
unhealthy weight reduction method and 36%
admitted to extreme weight loss methods
including crash dieting, fasting, diet pills, and
diuretic use under the assumption that these
methods were harmless. In sum, normal weight
women may choose to use weight loss products
for aesthetic purposes under the misperception
that such products are without health risk.
Women ,,\lith body image disturbances may
be at risk for abusing commercial weight loss
products and may misinterpret the advertisements for these products. Research on cognitive biases has found that people diagnosed
with an eating disorder tend to notice and
recall information related to food and body
shape. Research on cognitive biases has also
shown that normal weight women who are
overly concerned with body size and shape
(called body dysphoria) have information processing biases similar to women who meet the
diagnostic criteria for an eating disorder (7).
Cognitive biases are most prominent when
ambiguous stimuli related to fatness, dieting,
and control of food intake are presented. In a
recent review, Williamson (8) reports that
advertisements for weight loss products have
many of the ambiguous features of the stimuli
used in studies examining cognitive bias in
body dysphoria.
Marketing research has suggested that consumers often misinterpret or misuse information
presented in ads, particularly if the ad is ambigu0us or does not include a disclosure (9, 10). For
example, Burke et al. (11) found that consumers
may misinterpret information presented in
advertisements, but presenting truthful information/disclosures can serve to reduce such misinterpretations. Andrews et al. (9) examined how
consumers interpret nutrient content claims
made in advertisements. They found that the disclosures (in general) were successful in reducing
favorable evaluations of disease-risk and nutrient
content generalizations as compared to the no
disclosure control group.
The current study tested how an "at risk" population (Le., normal weight women with high
body dysphoria) processes information in weight

loss ads. The current study had two objectives: 1)
to investigate the potential effects of advertisements for weight loss products in normal weight
women high or low in body dysphoria, and 2) to
identify body image variables that may put normal weight women at risk for abusing weight
loss products, and that discriminate between
high and low body dysphoric groups.

METHOD
Weight loss products studied
Three different classes of weight loss products were included in the study: a prescription
obesity medication, a dietary fat substitute, and
an over-the-counter appetite suppressant.
Sibutramine (the prescription drug selected for
use in this study)' is an appetite suppressant
that works by inhibiting reuptake of norepinephrine, serotonin, and dopamine (12).
Sibutramine can only be obtained through a
physician's prescription, and it is only intended
for use in people who have obesity which causes significant health problems that are greater
than the potential side effects of the medication
(increased heart rate and blood pressure).
olestra (the dietary fat substitute selected for
use in this study) is a fat substitute that gives
food the same texture as fat but is not absorbed
from the intestine and does not contribute to
calories (3). One concern with this product is
that some people may believe that olestra has a
laxative effect, making it susceptible to abuse
by persons with eating disturbances (14). The
over-the-counter appetite suppressant selected
for use in this study contains phenylpropanolamine (PPA), a sympathomimetic
amine used to curb the appetite (15). 1 Each of
the three weight loss products contains a label
on the package describing possible side effects.
Participants
A total of 626 females enrolled at a major university were screened for inclusion in the study
sample. To be included in the study, participants
were required to 1) have high or low body dysphoria as defined by their score on the Body
Shape Questionnaire (BSQ) (16), 2) be in the normal body weight range, as defined by a body
mass index (BMI=kg/m2) between 20 and 25, and
3) be older than 18 years of age. Participants considered high in body dysphoria obtained a score
in the upper quartile on the BSQ, while participants considered low in body dysphoria obtained

lFollowing data collection in this study, phenylpropanolamine was taken off the market by the Food and Drug
Administration due to concerns about health risks associated with the use of this medication.
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a score in the lower quartile on the BSQ. Based
on data from Muller et al. (17), cut-off scores on
the BSQ for the upper and lower quartiles were
established (upper quartile ;:::118; lower quartile
~67; M=93.99, SD=35.02).
Of the 626 initially screened, 105 women (age
range == (8-41) participated in the second phase of
the study based on their classification as either
high or low body dysphoric and their self-reported normal weight. Participants were tested 1 day
to 1 week after the initial screening. The BSQ
was re-administered at the time of testing to
ensure that the test scores remained in the upper
or lower quartiles. Participants who obtained
BSQ scores within 5 points of the original cut-off
scores were included in the study (resulting in
new cut-off scores of 113 and 72 for high and
low body dysphoria respectively). Those who
scored greater than 5 points above or below the
cut-off score on the second administration of the
BSQ were excluded from the study. Participants
who had an eating disorder as defined by DSMIV or were not of normal weight were excluded
from the study. In the second phase of the study,
17 of the 105 participants were excluded from
the study because: a) BSQ scores were 5 points
above or below the cut-off (n=2); b) BMI was
below 20 or greater than 25 (n=12); or c) the
presence of an eating disorder (n=3). The final
sample consisted of 88 women, 45 with high
body dysphoria and 43 with low body dysphoria.
The mean weight of participants was 130 pounds
(SD=12.0 Ibs), and mean height was 64 inches
(SD=2.3 inches). The mean age of participants
did not differ across the high (M=19.4, SD=2.0)
and low (M=20.6, SD=4.0) body dysphoria
groups. This sample of women included a
diverse mixture of racial and ethnic groups: 76%
Caucasian, 13% African American, 6% Asian,
2.5% Hispanic, and 2.5% Native American.

Procedure
In the first phase of the study, participants
were screened using the BSQ and self-reported
height and weight. Participants who met the
primary inclusion criteria for the study were
asked to return. In the second phase of the
study, participants were told that the experiment was designed to assess consumer's attitudes about various products based on viewing
advertisements for those products. After viewing the ads, participants responded to the
dependent measures and a memory quiz included to test the participants' comprehension of
the information presented in the ads. Next, participants completed a questionnaire packet containing all other measures, were weighed and
measured, and screened for eating disorder
symptoms.
Eating Weight Disord., Vol. 8:.N. 2- 2003

Measures: Classification/screening
variables
Body Shape Questionnaire (BSO)
To examine our first study objective, a measure of body dysphoria was needed to classify
subjects as high or low in body dysphoria. As
previously stated, the BSQ was used. The BSQ is
a 34-item self-report questionnaire used to
assess concerns about body shape and size
where all items are scored on 6-point Likert
scales ranging from "never" to "always." The
term body dysphoria was coined by Williamson
et al. (18) to describe normal weight people who
are preoccupied \'Vith body size and shape (but
not other body concerns). Williamson hypothesized that this group of nonclinical subjects
would have many of the characteristics of people diagnosed v\rith eating disorders. In subsequent studies, the BSQ has proven to be useful
in defining nonclinical subjects of normal weight
status with weight concerns similar to eating
disordered patients (19).
Interview for the diagnosis of eating disorders - Fourth revision fIDED-IV)
The IDED-IV is a semi-structured clinical
interview found to be a valid and reliable
assessment instrument for diagnosing anorexia
nervosa, bulimia nervosa, binge eating disorder, and eating disorder not otherwise specified based on DSM-IV criteria (20). The IDEDIV was administered to participants as a
screening tool for the presence of an eating
disorder. Three participants were excluded
from participation based upon this screening
interview.

Measures: Independent/discriminator
variables
To examine our second objective, several
body-image related independent variables
were measured and used for discriminant
analyses. All of these measures were responded to in the second phase of the study, after the
experiment was conducted. These measures
are as follows:
Three-Factor Eating Questionnaire (TFEQ)
Restrictive eating attitudes were measured
with the three scales of the TFEQ: 1) dietary
restraint, 2) disinhibition, and 3) perceived
hunger. All three scales have been reported to
have good test-retest reliability (21). The
TFEQ was used to examine whether differing
levels of eating restraint are associated with
high ratings of intent to use weight loss products, and if the TFEQ scales were effective
discriminators of high and low body dysphoric groups.

Weight loss products and normal weight women
Psychosocial Risk Factors Questionnaire
(PRFQ)
The PRFQ is an 1S-item self-report measure
containing four sub-scales: 1) concern for physical appearance, 2) media pressure for thinness,
3) social pressure for thinness, and 4) perception of physical appearance. The PRFQ has
demonstrated adequate concurrent validity and
test-retest reliability for each of the four subscales (4). The PRFQ scales are used to examine
whether its sub-scales are associated with high
ratings of intent to use weight loss products,
and if they were effective discriminators of
high and low body dysphoric groups.
Beck Depression Inventory - Second edition
(EDI-II)
The BDHI is a 21-item self-report measure
designed to assess severity of depressive symptoms (22). The BDI-II was used to determine if it
was associated with high ratings of intent to
use weight loss products, and if it was an effective discriminator of high and low body dysphoric groups.

Measures: Dependent variables
Past Product Use
Past usage of diet products was assessed via
the following question for each of the three
products: Have you ever used the product or
one similar to it? (yes/no).
Intention and risk
For each product, participants completed
seven items adapted from Andrews et al. (9,
23) assessing behavioral intention to use the
product in the future and the perceived risk

TABLE 1
Disclosures for the three weight loss products.
Produd

Control version

Enhancement
version

Disclosure version
PPA

PPApilis
may cause
hypertension,
seizures, or
psychotic reactions.

When calling
10 place
your order,
mention this
advertisement.

PPAcan
makeweight
loss OOS~i
affordabe,
and fast.

Olesko

This product may
cause abdominal
cramping, nausea,
or diarrhea.

Look for
money-saving
coupons in
your local
newspaper.

Eat oieslra
to lose weight
and still
eat great.

For more
information
about sibutramine,
please contact
your physician.

Use sibutramine
to shed those
extra pounds
within weeks.

Sibutramine Sibutramine may
cause high
blood pressure,
insomnia
or conslipation.

associated with the product. This division was
based on theoretical grounds as well as
empirical evidence. The two questions comprising the behavioral intention scale ("How
likely would you be to use this product in the
future?" and "How often would you consider
using this product?") were highly correlated
(r =0.71, p<0.001) but were not highly correlated with the other three items. The remaining three questions comprised the perceived
risk scale ("Do you consider this product to
be healthy/unhealthy for you?" " Do you
agree/disagree that regular use of this product would contribute to the risk of health
problems?" and "Do you believe that the benefits gained from using this product regularly
would outweigh the risks involved?") and
were also positively correlated with r-values
ranging from 0.33 to 0.55) (Coefficient alpha =
0.67). Each question could be rated from O. to
4. Therefore, by adding the ratings, the range
of possible scores for the behavioral intention
scale was 0 to 8, and the range of possible
scores for the perceived risk scale was 0 to 12.

Advertising stimuli
The advertising stimuli consisted of three
experimental ads of weight loss products and six
dummy ads. The six dummy ads were included
as test stimuli in order to disguise the purpose of
the study and included the following products:
1) over-the-counter headache medication containing acetaminophines, aspirin and caffeine,
2) prescription contraceptive, medroxyprogesterone, 3) tampons, 4) prescription allergy medication, fexofenadine hydrochloride, 5) hair dye
and 6) whitening toothpaste. Original advertisements in published journals or magazines were
used. As previously stated, the experimental
products were olestra, sibutramine, and PPA.
Each product had three versions (nine ads total):
one containing additional information about the
health risks associated with the product (deterrence version), one containing additional information unrelated to the product's function (control version), and one containing additional
information intended to enhance perceptions of
the product's efficacy (enhancement version).
The information added to each of the weight loss
ads according to disclosure version is shown in
Table 1. All of the ads were in full color. For each
version of all nine ads (three experimental and
six dummy ads), additional information was
added at the bottom of the ad in a white box,
keeping font size and number of additional
words (nine words) constant across all ads.
Within the· entire study, each ad had trll'ee versions of product disclosure statements, but any
one participant viewed only one version of each
Eating
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ad with the same type of product disclosure
statement (deterrent, control, or enhancement)
for all of the weight loss ads.
Prior to initiation of the study, n,y-o steps were
taken in order to establish the content validity of
the advertising stimuli. First, n-vo expert judges,
each with over 15 years of research experience
in marketing and advertising research, rated the
advertisements. The raters were asked to examine each of the three versions of the weight loss
product advertisements and rate them according
to several dimensions. Expert ratings indicated
high levels of authenticity, salience, and consistency with actual advertising formats (mean ratings ranging from 5.0 to 6.3 on a 7-point Likert
type scale). The second step taken to ensure the
content validity of the ad stimuli was a pilot test
of the advertisements with college student participants. Participants included 30 undergraduate
females who viewed all nine advertisements.
After viewing each of the nine ads, participants
completed the dependent variable measures and
a four-item memory quiz concerning the content
of the advertisements. The quizzes were included
as a manipulation check to determine how well
participants attended to the information presented in the ads as well as to test the possibility of
fatigue effects. Participants were later asked
open-ended questions about what they thought
the study was about, whether or not they
believed that there was extra information added
to the ads, whether or not they noticed anything
strange about the ads, or if they thought the ads
appeared realistic. There was no order effect for
the quiz scores indicating the absence of a
fatigue effect, and none of the pmiicipants accurately guessed the purpose of the study.

RESULTS
Objective one: Comparisons for past
product usage, intention, and risk

We hypothesized that women with high levels
of body dysphoria would report higher past
usage of the weight loss products than would
women with low levels of body dysphoria. Table
2 summarizes percentages of positive and negative responses across the three different products as a function of level of body dysphoria. A
2X2 chi-square contingency table indicated that
responses to the question "Have you ever used
the product or one similar to it?" differed significantly as a function of body dysphoria for PPA
[X2 (1) = 15.10, p<0.0001] and sibutramine [X2 (1)
= 4.74, p<O.05]. That is, for PPA and sibu-

2The data pertaining to the 6 dummy ads were not analyzed.
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TABLE :2
use of the experimental weight los5 products.

Prior knowledge
"Hal/eyall
el/er heard

of !his
before?fl

aD
PPA

L

yes

110

X2

yes

110

9.3% 90.7%

2.3% 97.9%
0.30

H

15.1**'
46.7% 53.3%

4.4% 95.6%

76.7% 23.3%

97.7% 2.3%

Olestra

0.001
H

97.8% 2.2%

Sibutramine L

48.8% 5l.2%

3.4*
91.1% 8.9%
4.7% 95.3%

0.04
H

X2

46.7% 53.3%

4.7**
20.0% 80.0%

Note: BD = body dysphoria group; L =Iow; H =high,
·p<O.lO, '*p<O.05, ***p<O.Ol

tramine, participants with high levels of body
dysphoria reported increased prior use of the
product (or a similar product) as compared to
participants with low levels of body dysphoria.
There was only a marginally significant result
for olestra [X2 (1) = 3.40, p<0.10]. (As a data
check, responses to the question "Have you
ever heard of this product before?" did not differ across high and low body dysphoric groups
for any of the three weight loss products) (Table
2). Thus, the hypotheses that past usage would
be higher for the high dysphoric group was
supported for n-vo products, and was marginally supported for the third.
We also hypothesized that women with high
levels of body dysphoria would report a higher
intent to purchase and a lower perceived risk for
the weight loss products than would women
with low levels of body dysphoria. Multivariate
Analysis of variance (MAN OVA) was used to
evaluate group differences in ratings on intention and risk. A 2 (level of body dysphoria) x 3
Cad version) x 3 (product type) repeated measures MANOVA was used. The MANOVA was
performed with two between subjects factors
(level of body dysphoria and ad version) and one
vvithin subjects factor (product type).2 Significant
main effects were obtained for level of body dysphoria [F (2, 81) = 19.80, p<O.OOO1], product type
[F (4, 79) = 67.61, p<0.0001], and ad version [F (4,
164) = 2.43, p=0.05]. There were no significant
interactions between body dysphoria, ad version, or product type.

weight loss products and normal weight women

TABIf 3
Means and standard deviations on
Product
PPA

Product ail'itudes
questionllaire scale

level of body dysphoria

Moon

SO

Behavioral intentions

Low
High
Total

0.53
2.18
1.38

1.16
2.33
2.02

Total

9.70
9.04
9.36

2.26
2.15
2.22

Total

3.35
4.64
4.01

1]0
1.76
1.84

Total

4.81
4.40
4.60

2.79
2.43
2.61

Total

0.81
2.82
1.84

1.37
2.10
2.04

Total

7;58
6.84
7.20

2.35
2.31
2.34

Perceived risks

Olestra

Behavioral intentions

Perceived risks

Sibulramine

intentions scale and perceived risks scale for the three weight loss products.

low
High
low
High
Low
High

Behavioral intentions

low
High

Perceived risks

low
High

Analyses of variance (ANOVA) for each
dependent variable were conducted as followup tests to the MANOV A. The ANOVA for
main effect of level of body dysphoria was significant for the behavioral intention scale [F (1,
82) = 32.31, p<O.OOO1], but not for the perceived
risk scale [F (1,82) = 3.13, p>O.051. High body
dysphoria was associated with higher intent to
use PPA [F (1, 82) = 17.75, p<O.OOO1], olestra [F
(1, 82) = 12.84, p<O.05], and sibutramine [F (1,
82) = 27.71, p<O.0001]. There was no main effect
of body dysphoria for perceived risk associated
with PPA [F (1,82) = 1.86, pO.05], olestra [(F (1,
82)=0.51, p>0.05], or sibutramine [F (1,82) =
2.18, p>0.05]. Table 3 summarizes the means
and standard deviations for each of the three
products on the behavioral intention scale and
perceived risk scale.
A second hypothesis was that a "deterrent
disclosure" (Le., negative health side effects)
would result in the lowest behavioral intention
score and highest risk score in comparison to a
"control" (neutral information) or "enhancement disclosure" (Le., positive weight-loss
effects of the product). The only significant
effect for ad version was found for olestra
[F (2,82) = 4.48, p<0.05]. Tukey's HSD post hoc
analyses were conducted for the main effect of
ad version on the olestra intention scale to
determine which ad condition affected olestra
behavioral intention scores most strongly. The
olestra intention score for the deterrence disclosure (M=3.23, SD=2.18) was significantly
lower than the control CM=4.34, SD=1.59) and

enhancement (M=4.45, SD=1.48) ad versions.
The olestra intention scores for the control and
enhancement product disclosure statements
did not differ significantly. All interaction
effects involving ad version were nonsignficant
(p>O.05). These findings indicate that the risk
disclosure reduced behavioral intention to use
olestra, but did not significantly influence
intent to use the other weight loss products.
Univariate analyses also found significant differences among the behavioral intention [F
(2,164) = 92.9, p<O.0001] and perceived risk [F
(2,164) = 103.96, p<O.0001] scores for different
product types. Bonferroni adjusted pairwise
comparisons indicated that both high and low
body dysphoric groups rated olestra iArith significantly higher intentions to use and lower in
perceived risk than sibutramine and PPA. Sibutramine, a prescription medication, was rated
with higher behavioral intention to use and
lower in perceived risk than was PPA, an overthe-counter medication.
Objective two: Discriminators of high
intention, and high and low body
dysphoria

A third hypothesis was that women with the
highest levels of intention to use the weight
loss products would have higher scores on
measures of restrictive eating, concern for and
perception of physical appearance, social and
media pressure for thinness, and depression
when compared to women with lower intention
to use the three weight loss products. To test
Eating
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this hypothesis, discriminant function analysis
was conducted. This analysis tested whether
eight variables (PRFQ: concern for physical
appearance, media pressure for thinness, perception of physical appearance, social pressure
for thinness, BDI-II, TFEQ-restraint, disinhibition, and perceived hunger) differentiated
women who obtained high scores on the
behavioral intention scale for the three weight
loss products, Women were defined as having
high behavioral intention to use the products if
they obtained a behavioral intention score 1.5
SD or more above the mean for 2 out of the 3
weight loss products, PPA and sibutramine.
(Given the non-significant results for past
usage and intention results for olestra, it was
not used in these analyses.) According to these
criteria, 12 women were classified as having
high behavioral intention scores. Of these 12
women, 11 were in the high body dysphoria
group. A comparison group was obtained by
randomly selecting an additional 12 women
from the sample. The overall Wilks' Lambda
was significant, A=O.29, X2 (8)=19.67, p=O.012,
indicating that the two groups differed on their
psychological profiles. The top of Table 4 presents the standardized canonical discriminant
function coefficients as well as group means
and SD. The discriminant analysis found that
91 % of the individuals in the sample were correctly classified. Further, with the exception of
TFEQ-H, the means for the high intention
group were greater than the means for the low
intention group across variables (F-values
:2:14.21; p<0.01).
A fourth hypothesis was that the high body
dysphoria group would have higher scores on
measures of restrictive eating, concern for and
perception of physical appearance, social and
media pressure for thinness, and depression
when compared to the low body dysphoria
group. To test this hypothesis, discriminant
function analysis was conducted to determine if
the same eight variables differentiated women
previously classified as high (n=45) and low in
body dysphoria (n=43). The overall Wilks'
Lambda was significant, A=0.20, X2 (8) = 123.83,
p <0 .01, indicating that the tVI'O groups differed
on their psychological profiles. The bottom of
Table 4 presents the standardized canonical
discriminant function coefficients, group
means, and SD. The discriminant analysis
found that 100% of the individuals in the sample were correctly classified, and with the
exception of TFEQ-H, the means for the high
dysphoric group were greater than the means
for the low dysphoric group across variables
(F-values :2:29.46; p<O.01).
The results suggested that women who had
120

Eating weight Disord., VoL 8: N. 2- 2003

strong intentions to use these weight loss products exhibited higher
restraint, higher
thinness, lower
perceived social pressure
perceived physical attractiveness, higher concern for physical appearance, higher perceived
media pressure for thinness, higher susceptibility for overeating, and higher levels of depression. Thus, the participants who expressed
strong intentions to use these weight loss prod-

predictor variables with

Hypothesis 3: Standardized ,..""I+ir'''''''.
the discriminant
STandardized

Mea!l

scorers

Mean (51))
Controls

Variable
TFEQ-R

0.44

13.]0(4.18)

7.27{4.73)'

PRFQ-Sf'T

0.42

25.36 (2.91)

19.27(6.20)*

PRFQ-PPA

-0.42

14.64 (5.14)

21.18(5.34)'

PRFQ-CPA

0.40

29.54 (4.46)

22.18{7.52J*

PRfQ~MPT

0.37

24.09 (4.23)

17.91(6.64)"

TFEQ-D

0.36

10.36(4.18)

6.45(4.46)·

SDHI

0.35

19.82 (8.44)

1O.27{9.80)*

TFEQ-H

-0.07

7.09 (3.96)

7.82(3.54)

Hypothesis 4: Standardized coefficients and predictor variables with
the discriminant function
Standardized

Mean {SO)
dysphoria

Mean (SO)

!.ow dysphoria

with
fundion
Variable

0.51

11.86 (4.42)

PRFQ-SPT

0.25

24.31 (2.83)

17.08(5.10)'

PRfQ-PPA

-0.36

14.69 (4.60)

21.03(5.12)'

PRFQ-CPA

0.04

27.29 (5.35)

20.43 (6.0B)·

TFEQ-R

4.05 (3.21)*

PRfQ-MPT

0.42

23.12 (3.05)

14.43 (4.25)'

TfEQ-D

0.27

10.02 (3.23)

4.30 (3.84)'

SDH!

0.33

18.71(8.62)

5.10 (4.49)'

TfEQ-H

-0.03

9.00(3.54)

6.75 i8.52)

Nole: TFEQ-R '" Three-Fodor Eating Questionnaire Restrain! Scale; PRFQ-SPT '"
Psychosocial Risk factors Quesfionnaire Social Pressure for Thinness Scale; PRFQ·
PPA '" Psychosocial Risk foelors Questionnaire Perception of Physical
Attractiveness Scale; PRFQ-CPA = Psychosocial Risk Factors Questionnaire
Concern for Physico! Appearance Scale; PRFQ-MPT =Psychosocial Risk fadors
Questionnaire Media Pressure for Thinness Scale; TFEQ-D = Three-factor Eating
Questionnaire Disinhibition Scale; SOH! = Seck Depression Inventory-Second
Edition; TfEQ-H '" Three-Factor Eating Questionnaire Perceived Hunger Scale
'Differences belween groups are significant at the 0.01 !evel.

weight loss products and normal weight women
ucts displayed many of the characteristics of
persons diagnosed with an eating disorder but
did not report the severity of symptoms that
are commonly associated with eating disorders. Similarly, high body dysphoric women
scored higher than low body dysphoric women
on the same seven body image variables.

DISCUSSION
Before discussing the findings of the study, it
is important to recognize some of the limitations of the study. The participants were young
American women and the results should not be
generalized to other cultures since many ethnic
groups were not represented and the sample
size was too small to allow for analyses of different ethnic groups. Also, the findings are
based purely upon self-report of the participants. Therefore, we cannot conclude that
these participants did in fact use the weight
loss products simply because they reported an
intention to do so. The results should be interpreted in the context of these considerations.
This study tested how normal weight women
with body dysphoria responded to information
in weight loss ads. In addition, this study examined select body image variables that contribute to an "at risk" group's intention to
abuse weight loss products, and that discriminate between high and low body dysphoric
groups. The hypothesis that normal weight
women with high body dysphoria would have
higher past usage and intention to use weight
reduction products than would women with
low levels of body dysphoria was largely supported. Specifically, high body dysphoric
women reported higher intention to use the
products in the future as well as actual higher
prior use of two of the three weight loss products. However, women with high and low body
dysphoria did not differ in their perceived risks
for using the products, and in general, participants rated the weight loss products as having
some health risks. (The overall means for risk,
on a 0 to 12 scale, were 9.36 for PP A; 7.2 for
sibutramine; and 4.6 for olestra.) This pattern
of findings suggests that normal weight
women "vith high levels of body dysphoria did
not believe that these weight loss products
were harmless. They recognized potential
health risks associated with using such products, but nonetheless, expressed stronger
intention to use these weight loss products.
In the context of research on cognitive biases
associated with body dysphoria, these findings
suggest that information processing with these
ads was not completely unbiased. It is likely

that high body dysphoric women had preexisting (and more favorable) attitudes about
weight-loss products. Research on cognitive
biases has postulated that strongly held beliefs
Cschemas) influence the processing of food and
diet related information, resulting in unhealthy
behavior to control body weight and shape (7).
Our findings are consistent with this view.
The hypothesis that risk and intention would
be affected by type of disclosure was not supported for two of three products. (Only olestra
showed an effect). This finding is not consistent
with the findings of previous studies (11, 24). One
possible explanation might be that the ratings for
intent to use PPA and sibutramine were generally low across all participants (i.e., 1.38 for PPA
and 1.84 for sibutramine on a scale of 0 to 8).
Thus, a "floor" effect may have been operating
making it difficult to detect the impact of deterrent disclosures. In comparison, the olestra ratings were much higher than the PPA or sibutramine ratings, which may have allowed the
finding of a suppressive effect for the deterrent
risk disclosure. These results are consistent,
however, with research demonstrating that shnilar disclosures can have different effects across
product categories that are viewed differently in
terms of initial attitudes and risk (cf. 9 vs 23).
There was no effect of ad disclosure on perceived risk for any of the products. Even when
risk factor information was added to the ads,
participants did not rate the product as having
more potential health risks, suggesting that
women may have prior beliefs about the relative
risks of certain products that are unchanged by
information presented in the ads. This finding
may have implications for future advertisement
regulations, demonstrating the relative ineffectiveness of warning labels and health risk disclosures for certain types of products. Women with
high body dysphoria indicated a general understanding of the risks involved with using the
weight loss products regardless of wpich type of
ad disclosure they received; however, knowledge
of such health risks does not appear to be a
deterrent for future use of such products.
Perhaps reading about possible side effects is not
an effective deterrent because it is not personally
salient to the person. Future research should
focus on developing effective methods for deterring the inappropriate use of products that are
potentially harmful.
Though hypotheses were not formally
advanced with regard to product type, participants in both groups exhibited a similar pattern
of responding. Olestra was the most highly
rated product (in terms of lowest risk and highest intention) followed by sibutramine and PPA.
It is not surprising that olestra was the most
Eating
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higbJy rated given that potato chips containing
olestra are an easily accessible product even
though the olestra L,l1gredient has been criticized
by the Center for Science in the Public Interest
for absorption and nutrient deprivation problems (25). However, the fact that ratings for
sibutramine, a prescription medication, were
more favorable than the ratings for PP A, an
over-the-counter medication, was unexpected. A
possible explanation for this is that people may
be more trusting of medications that must be
prescribed by a physician, thus affecting risk
and intention. Thus, it is possible that prescription medications may be at higher risk for abuse
compared to OTC medications. A Significant
number of participants reported prior use of the
weight loss products despite their normal
weight status. It was especially alarming that
eleven women (20% of the high body dysphoria
group) reported prior use of a prescription obesity medication even though they were of normal weight. These products are explicitly not
recommended for people who are not clinically
obese because of the risk of side effects associated "vith use of the medications. Additionally, a
large proportion of the women in the high body
dysphoria group (47%) reported prior use of
PP A or other OTC appetite suppressants. It is
possible that the women who reported prior use
of a prescription obesity medication or OTC
appetite suppressant were obese while using the
product, and lost enough weight to fall within a
normal weight range and be eligible for participation in this study. However, given the serious
side effect profile of these medications, future
studies should address the question of the
attainability of these medications and what measures could be taken to monitor improper use of
such medications.
The results of the discriminant analyses show
that a subset of normal weight women rated
their intentions to use weight loss products significantly higher than the rest of the sample.
Women at risk for inappropriate use of these
products tended to actively restrain their eating,
feel high pressure for thinness, and have higher
levels of depression. Further, these same variables discriminated high and low body dysphoric
groups. These results suggest that it is important
for healthcare professionals and regulatory
agencies to effectively identify women who are
normal weight that are motivated to use potentially harmful weight loss products. Thus, mental
health professionals as well as physicians may be
able to identify those women who are willing to
use extreme measures to attain weight loss by
using simple self-report measures such as those
utilized in the present study.
In summary, the results of this study suggest
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that there is cause for concern regarding
potential misuse of weight loss products.
Advertisements featuring the products used in
this study as well as countless others are growing in number. Women who do not need to
lose weight but have significant body image
concerns appear to be willing to use potentially
harmful weight loss products despite the
knowledge that such products may pose significant health risks. Techniques utilized by advertising regulatory agencies such as warning
labels do not appear to have a strong deterrent
effect with normal weight women who are
enrolled in college. Future research in this area
should focus on developing ways to prevent the
misuse of weight loss products through advertising, medical and mental health screenings,
and improved product labels. For example,
more creative policy measures may be needed,
such as the use of prominent "black box" warnings employed for "fen-ph en" (26), and other
visual cues for conveying risk information.
Such disclosures may help at-risk women make
more informed decisions. However, given that
our results show that women high in body dysphoria understand the risks, but largely choose
to ignore such risks, stronger control of such
products may be needed. For example, it has
been suggested that many doctors and clinics
have attracted "at-risk" populations via ads for
products that claim safe vveight loss. Our
results pertaining to sibutramine and related
prescription weight loss products are consistent with this suggestion. It may be that federal
agencies, such as the FDA, FTC, and CDC,
need to become more involved in the dissemination of risk information and in the regulation
of the health care professionals' role in the promotion of weight loss products.
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